```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene,
biobusiness
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1         2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
   9 FILES SEARCHED...
L2          193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3            0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2   ANSWER 1 OF 193  USPATFULL on STN
TI     Novel proteins and nucleic acids encoding same
AB     Disclosed herein are nucleic acid sequences that encode novel
       polypeptides. Also disclosed are polypeptides encoded by these nucleic
       acid sequences, and antibodies, which immunospecifically-bind to the
       polypeptide, as well as derivatives, variants, mutants, or fragments of
       the aforementioned polypeptide, polynucleotide, or antibody. The
       invention further discloses therapeutic, diagnostic and research methods
       for diagnosis, treatment, and prevention of disorders involving any one
       of these novel human nucleic acids and proteins.

ACCESSION NUMBER:        2004:13595  USPATFULL
TITLE:                   Novel proteins and nucleic acids encoding same
INVENTOR(S):             Zerhusen, Bryan D., Branford, CT, UNITED STATES
                         Padigaru, Muralidhara, Branford, CT, UNITED STATES
                         Spytek, Kimberly, New Haven, CT, UNITED STATES
                         Spaderna, Steven, Berlin, CT, UNITED STATES
                         Gangolli, Esha A., Branford, CT, UNITED STATES
                         Rastelli, Luca, Guilford, CT, UNITED STATES
```

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Shimkets, Richard, West Haven, CT, UNITED STATES
Mishra, Vishnu, Branford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Szekeres, Edward S., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010118	A1	20040115	
APPLICATION INFO.:	US 2001-930512	A1	20010815	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225692P	20000816 (60)
	US 2000-225693P	20000816 (60)
	US 2000-225837P	20000816 (60)
	US 2000-226236P	20000818 (60)
	US 2000-226353P	20000818 (60)
	US 2000-227085P	20000822 (60)
	US 2000-227395P	20000823 (60)
	US 2000-227492P	20000824 (60)
	US 2000-227600P	20000824 (60)
	US 2001-275952P	20010314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
TI Methods of treatment of periodontal disease
AB Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
TITLE: Methods of treatment of periodontal disease
INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
Wozney, John M., Hudson, MA, UNITED STATES
Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009916	A1	20040115	
APPLICATION INFO.:	US 2003-397214	A1	20030327	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889 Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328 Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN
TI Chondrogenic and osteogenic inducing molecule
AB The present invention is directed to methods of using and compositions comprising amelogenin peptides capable of inducing chondrogenesis and osteogenesis when implanted in vivo, a chondrogenesis in cultures in vitro. Compositions and methods of enhancing bone and cartilage growth using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6677306	B1	20040113	
	WO 2000006734		20000210	
APPLICATION INFO.:	US 2001-744128		20010516	(9)
	WO 1999-US17342		19990729	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Marshall, Gerstein & Borun LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1877

L2 ANSWER 4 OF 193 USPATFULL on STN
TI Treatment of inflammatory bowel disease using growth factors
AB The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

factors

INVENTOR(S): Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Jeffers, Michael E., Branford, CT, UNITED STATES
LaRochelle, William J., Madison, CT, UNITED STATES
Lichenstein, Henri S., Guilford, CT, UNITED STATES
Peterson, Jeffrey, Brookfield, CT, UNITED STATES
Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
Rittman, Beth, Colchester, CT, UNITED STATES
Shimkets, Juliette B., Guilford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 7115

L2 ANSWER 5 OF 193 USPATFULL on STN
TI Proteins and nucleic acids encoding same
AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
TITLE: Proteins and nucleic acids encoding same
INVENTOR(S): Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., North Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Edinger, Schlomit, New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010820 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 17887

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN
TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:318756 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING

PRIORITY INFORMATION:	NUMBER	DATE
	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN
TI Sulfonamide compounds
AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:306969 USPATFULL
TITLE: Sulfonamide compounds
INVENTOR(S): Billledeau, Roland Joseph, Santa Clara, CA, UNITED STATES
Broka, Chris Allen, Foster City, CA, UNITED STATES
Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES
Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES
Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES
Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 3904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN
TI OSTEOPROTEGERIN
AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:294810 USPATFULL
TITLE: OSTEOPROTEGERIN
INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Page(s)
LINE COUNT: 5457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
L1 2849 S ALBUMIN FUSION PROTEIN
L2 193 S BMP-1 AND ALBUMIN
L3 0 S L2 AND L1

=> s l1 and FGF-16

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.21        0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s Rantes
L1       13014 RANTES

=> s albumin fusion protein
L2        2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3           8 L1 AND L2

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 8  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
```

	US 2000-229358P 20000412 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	25066

L3 ANSWER 2 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	15415		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN
TI Neutrokine-alpha and neutrokine-alpha splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokine-alpha and neutrokine-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed

on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING

PRIORITY INFORMATION:

NUMBER	DATE
US 2001-329508P	20011017 (60)
US 2001-329747P	20011018 (60)
US 2001-330835P	20011031 (60)
US 2001-331478P	20011116 (60)
US 2001-336726P	20011207 (60)
US 2002-368548P	20020401 (60)
US 2000-225628P	20000815 (60)
US 2000-227008P	20000823 (60)
US 2000-234338P	20000922 (60)
US 2000-240806P	20001017 (60)
US 2000-250020P	20001130 (60)
US 2001-276248P	20010316 (60)
US 2001-293499P	20010525 (60)
US 2001-296122P	20010607 (60)
US 2001-304809P	20010713 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)
US 1999-142659P	19990706 (60)
US 1999-145824P	19990727 (60)
US 1999-167239P	19991124 (60)
US 1999-168624P	19991203 (60)
US 1999-171108P	19991216 (60)
US 1999-171626P	19991223 (60)
US 2000-176015P	20000114 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)

	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN
TI Chemokine beta-1 fusion proteins
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:206834 USPATFULL			
TITLE:	Chemokine beta-1 fusion proteins			
INVENTOR(S):	Bell, Adam, Germantown, MD, UNITED STATES			
	Ruben, Steven M., Olney, MD, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143191	A1	20030731	
APPLICATION INFO.:	US 2002-153604	A1	20020524	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-293212P		20010525	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	21 Drawing Page(s)			
LINE COUNT:	15446			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES			
	Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN
TI Binding polypeptides and methods based thereon
AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 11834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

=> s FGF-8
L4 1364 FGF-8

=> s l4 and albumin
L5 509 L4 AND ALBUMIN

```
=> s l5 and fusion
L6          491 L5 AND FUSION

=> d l6 and l1
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l6 and l1
L7          207 L6 AND L1

=> s l7 and stabilizer
L8            0 L7 AND STABILIZER

=> d l7 ti abs ibib 1-10

L7   ANSWER 1 OF 207  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion
       proteins. Nucleic acid molecules encoding the albumin
       fusion proteins of the invention are also encompassed by the
       invention, as are vectors containing these nucleic acids, host cells
       transformed with these nucleic acids vectors, and methods of making the
       albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating,
       preventing, or ameliorating diseases, disordrs or conditions using
       albumin fusion proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
                         US 2000-229358P    20000412 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                         ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:        29
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      18 Drawing Page(s)
LINE COUNT:              25066

L7   ANSWER 2 OF 207  USPATFULL on STN
TI     53 human secreted proteins
AB     The present invention relates to novel human secreted proteins and
       isolated nucleic acids containing the coding regions of the genes
       encoding such proteins. Also provided are vectors, host cells,
       antibodies, and recombinant methods for producing human secreted
       proteins. The invention further relates to diagnostic and therapeutic
       methods useful for diagnosing and treating diseases, disorders, and/or
       conditions related to these novel human secreted proteins.

ACCESSION NUMBER:        2004:13609  USPATFULL
```

TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139
Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010121	A1	20040115	
APPLICATION INFO.:	US 2003-333900	A1	20030124	(10)
	WO 2001-US8585		20010316	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L7 ANSWER 4 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009491	A1	20040115	
APPLICATION INFO.:	US 2002-264237	A1	20021004	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L7 ANSWER 5 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)

US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN
TI Apoptosis inducing molecule II and methods of use
AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
TITLE: Apoptosis inducing molecule II and methods of use
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Zhai, Yifan, Rockville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743 Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520 Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254 Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Page(s)
LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L7 ANSWER 8 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)

US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)

	US 2000-190076P 20000317 (60)
	US 2000-209467P 20000607 (60)
	US 2000-205515P 20000519 (60)
	US 2001-259678P 20010105 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	27694

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL
TITLE:	Nucleic acids, proteins, and antibodies
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)

US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

```
     (FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
     BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
L1         13014 S RANTES
L2          2849 S ALBUMIN FUSION PROTEIN
L3             8 S L1 AND L2
L4          1364 S FGF-8
L5           509 S L4 AND ALBUMIN
L6           491 S L5 AND FUSION
L7           207 S L6 AND L1
L8             0 S L7 AND STABILIZER

=> s fusion partner
L9          6424 FUSION PARTNER

=> s l9 and albumin
L10         2467 L9 AND ALBUMIN

=> s l9 and BMP
L11          176 L9 AND BMP

=> s l11 and l10
L12          141 L11 AND L10

=> s l12 and l1
L13          101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13  ANSWER 1 OF 101  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins.
       Nucleic acid molecules encoding the albumin fusion proteins of
       the invention are also encompassed by the invention, as are vectors
       containing these nucleic acids, host cells transformed with these
       nucleic acids vectors, and methods of making the albumin
       fusion proteins of the invention and using these nucleic acids, vectors,
       and/or host cells. Additionally the present invention encompasses
       pharmaceutical compositions comprising albumin fusion proteins
       and methods of treating, preventing, or ameliorating diseases, disordrs
       or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
                         US 2000-229358P    20000412 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                         ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:        29
EXEMPLARY CLAIM:         1
```

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L13 ANSWER 3 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)

US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L13 ANSWER 4 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L13 ANSWER 5 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)

US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)

	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	27694	

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL		
TITLE:	Nucleic acids, proteins, and antibodies		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES		
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)	
	US 2000-180628P	20000204 (60)	
	US 2000-214886P	20000628 (60)	
	US 2000-217487P	20000711 (60)	
	US 2000-225758P	20000814 (60)	
	US 2000-220963P	20000726 (60)	
	US 2000-217496P	20000711 (60)	
	US 2000-225447P	20000814 (60)	
	US 2000-218290P	20000714 (60)	
	US 2000-225757P	20000814 (60)	
	US 2000-226868P	20000822 (60)	
	US 2000-216647P	20000707 (60)	

US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)

US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)

US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)

US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
US 2000-179065P 20000131 (60)

US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)

US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)

	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN
TI Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AB Described herein are methods and compositions that can be used for diagnosis and treatment of metastatic colorectal cancer. Also described herein are methods that can be used to identify modulators of metastatic colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334944 USPATFULL
TITLE: Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235820	A1	20031225
APPLICATION INFO.:	US 2002-87080	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 22670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

```
L4          1364 S FGF-8
L5           509 S L4 AND ALBUMIN
L6           491 S L5 AND FUSION
L7           207 S L6 AND L1
L8             0 S L7 AND STABILIZER
L9          6424 S FUSION PARTNER
L10         2467 S L9 AND ALBUMIN
L11          176 S L9 AND BMP
L12          141 S L11 AND L10
L13          101 S L12 AND L1

=> s albumin () fusion protein
L14        2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP
L15           0 ALBUMIN (W) BMP

=> s albumin ()FGF
L16          35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16   ANSWER 1 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58432  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
      vivo. The isolated nucleic acid molecules may be used directly in cell or
      gene therapy applications to treat or prevent liver disorders, including
      hepatic cirrhosis, fulminant liver failure, damage caused by acute viral
      hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAY58432  Protein       DGENE
TITLE:            Fibroblast growth factor family polypeptide which stimulates
                  proliferation and growth of hepatocytes is useful for
                  treating hepatic disorders -
INVENTOR:         Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE:  (AMGE-N)AMGEN INC.
PATENT INFO:      US 5998170    A  19991207                33p
APPLICATION INFO: US 1997-943915   19971003
PRIORITY INFO:    US 1997-943915   19971003
DOCUMENT TYPE:    Patent
LANGUAGE:         English
OTHER SOURCE:     2000-085497 [07]
DESCRIPTION:      Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16   ANSWER 2 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58431  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
```

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.
ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.
ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a pAMG21 vector PCR primer used to ascertain that a pAMG21/rat FGF-16 construct had been produced in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.
ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55804 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55804 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55803 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55802 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55802 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55801 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55800 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55800 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55799 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55799 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID NO:14.

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55798 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55798 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55797 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55794 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55793 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58429
DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55790 cDNA DGENE
AB This sequence represents cDNA encoding rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55790 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58428
DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2
L4 1364 S FGF-8
L5 509 S L4 AND ALBUMIN
L6 491 S L5 AND FUSION
L7 207 S L6 AND L1
L8 0 S L7 AND STABILIZER
L9 6424 S FUSION PARTNER
L10 2467 S L9 AND ALBUMIN
L11 176 S L9 AND BMP
L12 141 S L11 AND L10
L13 101 S L12 AND L1
L14 2849 S ALBUMIN () FUSION PROTEIN
L15 0 S ALBUMIN () BMP
L16 35 S ALBUMIN ()FGF

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1 File: USPT Jan 7, 1986

US-PAT-NO: 4563489
DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Urist; Marshall R.	Pacific Palisades	CA		

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
albumin adj2 BMP	1

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2 File: USPT Feb 15, 2000

US-PAT-NO: 6025194
DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence asssociated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: 435/320.1; 435/325, 536/23.1, 536/23.5, 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. De

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2 File: USPT Mar 31, 1998

US-PAT-NO: 5733541
DOCUMENT-IDENTIFIER: US 5733541 A
** See image for Certificate of Correction **

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: 424/93.1; 424/93.7, 435/325, 435/347, 435/373, 435/375, 435/377

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. De

h e b b g e e e f e ef b e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
BMP-2 and L7	2

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: albumin and fusion protein

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Friday, January 16, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L10	l9 adj BMP	980	L10
L9	albumin fusion protein	198014	L9
L8	BMP-2 and L7	2	L8
L7	L6 and IL-6	284	L7
L6	L5 and Rantes	838	L6
L5	human chemokine and albumin	314787	L5
L4	albumin adj2 CXC3	0	L4
L3	albumin fused to BMP	159316	L3
L2	albumin adj2 BMP	1	L2
L1	albumin and fusion protein	144237	L1

END OF SEARCH HISTORY

h e b b g e e e e f ff e ch

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene,
biobusiness
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1         2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
   9 FILES SEARCHED...
L2          193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3            0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2   ANSWER 1 OF 193  USPATFULL on STN
TI     Novel proteins and nucleic acids encoding same
AB     Disclosed herein are nucleic acid sequences that encode novel
       polypeptides. Also disclosed are polypeptides encoded by these nucleic
       acid sequences, and antibodies, which immunospecifically-bind to the
       polypeptide, as well as derivatives, variants, mutants, or fragments of
       the aforementioned polypeptide, polynucleotide, or antibody. The
       invention further discloses therapeutic, diagnostic and research methods
       for diagnosis, treatment, and prevention of disorders involving any one
       of these novel human nucleic acids and proteins.

ACCESSION NUMBER:        2004:13595  USPATFULL
TITLE:                   Novel proteins and nucleic acids encoding same
INVENTOR(S):             Zerhusen, Bryan D., Branford, CT, UNITED STATES
                         Padigaru, Muralidhara, Branford, CT, UNITED STATES
                         Spytek, Kimberly, New Haven, CT, UNITED STATES
                         Spaderna, Steven, Berlin, CT, UNITED STATES
                         Gangolli, Esha A., Branford, CT, UNITED STATES
                         Rastelli, Luca, Guilford, CT, UNITED STATES
```

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Shimkets, Richard, West Haven, CT, UNITED STATES
Mishra, Vishnu, Branford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Szekeres, Edward S., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010118	A1	20040115
APPLICATION INFO.:	US 2001-930512	A1	20010815 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225692P	20000816 (60)
	US 2000-225693P	20000816 (60)
	US 2000-225837P	20000816 (60)
	US 2000-226236P	20000818 (60)
	US 2000-226353P	20000818 (60)
	US 2000-227085P	20000822 (60)
	US 2000-227395P	20000823 (60)
	US 2000-227492P	20000824 (60)
	US 2000-227600P	20000824 (60)
	US 2001-275952P	20010314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
TI Methods of treatment of periodontal disease
AB Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
TITLE: Methods of treatment of periodontal disease
INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
Wozney, John M., Hudson, MA, UNITED STATES
Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009916	A1	20040115
APPLICATION INFO.:	US 2003-397214	A1	20030327 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889 Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328 Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN
TI Chondrogenic and osteogenic inducing molecule
AB The present invention is directed to methods of using and compositions comprising amelogenin peptides capable of inducing chondrogenesis and osteogenesis when implanted in vivo, a chondrogenesis in cultures in vitro. Compositions and methods of enhancing bone and cartilage growth using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6677306	B1	20040113	
	WO 2000006734		20000210	
APPLICATION INFO.:	US 2001-744128		20010516	(9)
	WO 1999-US17342		19990729	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Marshall, Gerstein & Borun LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1877

L2 ANSWER 4 OF 193 USPATFULL on STN
TI Treatment of inflammatory bowel disease using growth factors
AB The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

factors

INVENTOR(S): Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Jeffers, Michael E., Branford, CT, UNITED STATES
LaRochelle, William J., Madison, CT, UNITED STATES
Lichenstein, Henri S., Guilford, CT, UNITED STATES
Peterson, Jeffrey, Brookfield, CT, UNITED STATES
Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
Rittman, Beth, Colchester, CT, UNITED STATES
Shimkets, Juliette B., Guilford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 7115

L2 ANSWER 5 OF 193 USPATFULL on STN
TI Proteins and nucleic acids encoding same
AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
TITLE: Proteins and nucleic acids encoding same
INVENTOR(S): Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., North Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Edinger, Schlomit, New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010820 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 17887

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN
TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:318756 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN
TI Sulfonamide compounds
AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:306969 USPATFULL
TITLE: Sulfonamide compounds
INVENTOR(S): Billledeau, Roland Joseph, Santa Clara, CA, UNITED STATES
Broka, Chris Allen, Foster City, CA, UNITED STATES
Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES
Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES
Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES
Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 3904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN
TI OSTEOPROTEGERIN
AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:294810 USPATFULL
TITLE: OSTEOPROTEGERIN
INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Page(s)
LINE COUNT: 5457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
L1 2849 S ALBUMIN FUSION PROTEIN
L2 193 S BMP-1 AND ALBUMIN
L3 0 S L2 AND L1

=> s l1 and FGF-16

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

```
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.21       0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s Rantes
L1       13014 RANTES

=> s albumin fusion protein
L2        2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3           8 L1 AND L2

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 8  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
```

	US 2000-229358P 20000412 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	25066

L3 ANSWER 2 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL		
TITLE:	Albumin fusion proteins		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-256931P		20001221 (60)
	US 2000-199384P		20000425 (60)
	US 2000-229358P		20000412 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Page(s)		
LINE COUNT:	15415		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN
TI Neutrokine-alpha and neutrokine-alpha splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokine-alpha and neutrokine-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed

on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING

PRIORITY INFORMATION:

NUMBER	DATE
US 2001-329508P	20011017 (60)
US 2001-329747P	20011018 (60)
US 2001-330835P	20011031 (60)
US 2001-331478P	20011116 (60)
US 2001-336726P	20011207 (60)
US 2002-368548P	20020401 (60)
US 2000-225628P	20000815 (60)
US 2000-227008P	20000823 (60)
US 2000-234338P	20000922 (60)
US 2000-240806P	20001017 (60)
US 2000-250020P	20001130 (60)
US 2001-276248P	20010316 (60)
US 2001-293499P	20010525 (60)
US 2001-296122P	20010607 (60)
US 2001-304809P	20010713 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)
US 1999-142659P	19990706 (60)
US 1999-145824P	19990727 (60)
US 1999-167239P	19991124 (60)
US 1999-168624P	19991203 (60)
US 1999-171108P	19991216 (60)
US 1999-171626P	19991223 (60)
US 2000-176015P	20000114 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)

	US 1999-142659P	19990706	(60)
	US 1999-145824P	19990727	(60)
	US 1999-167239P	19991124	(60)
	US 1999-168624P	19991203	(60)
	US 1999-171108P	19991216	(60)
	US 1999-171626P	19991223	(60)
	US 2000-176015P	20000114	(60)
	US 1997-36100P	19970114	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN
TI Chemokine beta-1 fusion proteins
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:206834 USPATFULL			
TITLE:	Chemokine beta-1 fusion proteins			
INVENTOR(S):	Bell, Adam, Germantown, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143191	A1	20030731	
APPLICATION INFO.:	US 2002-153604	A1	20020524	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-293212P		20010525	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	21 Drawing Page(s)			
LINE COUNT:	15446			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN
TI Binding polypeptides and methods based thereon
AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003091565	A1	20030515	
APPLICATION INFO.:	US 2001-932613	A1	20010817	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 11834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

=> s FGF-8
L4 1364 FGF-8

=> s l4 and albumin
L5 509 L4 AND ALBUMIN

```
=> s l5 and fusion
L6          491 L5 AND FUSION

=> d l6 and l1
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l6 and l1
L7          207 L6 AND L1

=> s l7 and stabilizer
L8            0 L7 AND STABILIZER

=> d l7 ti abs ibib 1-10

L7   ANSWER 1 OF 207  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion
       proteins. Nucleic acid molecules encoding the albumin
       fusion proteins of the invention are also encompassed by the
       invention, as are vectors containing these nucleic acids, host cells
       transformed with these nucleic acids vectors, and methods of making the
       albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating,
       preventing, or ameliorating diseases, disordrs or conditions using
       albumin fusion proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
                         US 2000-229358P    20000412 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                         ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:        29
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      18 Drawing Page(s)
LINE COUNT:              25066

L7   ANSWER 2 OF 207  USPATFULL on STN
TI     53 human secreted proteins
AB     The present invention relates to novel human secreted proteins and
       isolated nucleic acids containing the coding regions of the genes
       encoding such proteins. Also provided are vectors, host cells,
       antibodies, and recombinant methods for producing human secreted
       proteins. The invention further relates to diagnostic and therapeutic
       methods useful for diagnosing and treating diseases, disorders, and/or
       conditions related to these novel human secreted proteins.

ACCESSION NUMBER:        2004:13609  USPATFULL
```

TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139
Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010121	A1	20040115	
APPLICATION INFO.:	US 2003-333900	A1	20030124	(10)
	WO 2001-US8585		20010316	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L7 ANSWER 4 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009491	A1	20040115	
APPLICATION INFO.:	US 2002-264237	A1	20021004	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L7 ANSWER 5 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)

US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN

TI Apoptosis inducing molecule II and methods of use

AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
TITLE: Apoptosis inducing molecule II and methods of use
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Zhai, Yifan, Rockville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743 Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520 Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254 Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Page(s)
LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L7 ANSWER 8 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)

US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)

	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	27694	

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL		
TITLE:	Nucleic acids, proteins, and antibodies		
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES		
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)	
	US 2000-180628P	20000204 (60)	
	US 2000-214886P	20000628 (60)	
	US 2000-217487P	20000711 (60)	
	US 2000-225758P	20000814 (60)	
	US 2000-220963P	20000726 (60)	
	US 2000-217496P	20000711 (60)	
	US 2000-225447P	20000814 (60)	
	US 2000-218290P	20000714 (60)	
	US 2000-225757P	20000814 (60)	

US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)

US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

```
L1         13014 S RANTES
L2          2849 S ALBUMIN FUSION PROTEIN
L3             8 S L1 AND L2
L4          1364 S FGF-8
L5           509 S L4 AND ALBUMIN
L6           491 S L5 AND FUSION
L7           207 S L6 AND L1
L8             0 S L7 AND STABILIZER

=> s fusion partner
L9          6424 FUSION PARTNER

=> s l9 and albumin
L10         2467 L9 AND ALBUMIN

=> s l9 and BMP
L11          176 L9 AND BMP

=> s l11 and l10
L12          141 L11 AND L10

=> s l12 and l1
L13          101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13  ANSWER 1 OF 101  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins.
       Nucleic acid molecules encoding the albumin fusion proteins of
       the invention are also encompassed by the invention, as are vectors
       containing these nucleic acids, host cells transformed with these
       nucleic acids vectors, and methods of making the albumin
       fusion proteins of the invention and using these nucleic acids, vectors,
       and/or host cells. Additionally the present invention encompasses
       pharmaceutical compositions comprising albumin fusion proteins
       and methods of treating, preventing, or ameliorating diseases, disordrs
       or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
                         US 2000-229358P    20000412 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                         ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:        29
EXEMPLARY CLAIM:         1
```

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L13 ANSWER 3 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L13 ANSWER 4 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L13 ANSWER 5 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)

US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)

	US 2000-205515P 20000519 (60)
	US 2001-259678P 20010105 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	27694

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL
TITLE:	Nucleic acids, proteins, and antibodies
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)

US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)

US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE°
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)

US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a pAMG21 vector PCR primer used to ascertain that a pAMG21/rat FGF-16 construct had been produced in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.
ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.
ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55804 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55804 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55803 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55802 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55802 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55801 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55800 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55800 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55799 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55799 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID NO:14.

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55798 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55798 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55797 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55794 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55793 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58429
DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55790 cDNA DGENE
AB This sequence represents cDNA encoding rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55790 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58428
DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2
L4 1364 S FGF-8
L5 509 S L4 AND ALBUMIN
L6 491 S L5 AND FUSION
L7 207 S L6 AND L1
L8 0 S L7 AND STABILIZER
L9 6424 S FUSION PARTNER
L10 2467 S L9 AND ALBUMIN
L11 176 S L9 AND BMP
L12 141 S L11 AND L10
L13 101 S L12 AND L1
L14 2849 S ALBUMIN () FUSION PROTEIN
L15 0 S ALBUMIN () BMP
L16 35 S ALBUMIN ()FGF

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1 File: USPT Jan 7, 1986

US-PAT-NO: 4563489
DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Urist; Marshall R.	Pacific Palisades	CA		

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
albumin adj2 BMP	1

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2 File: USPT Feb 15, 2000

US-PAT-NO: 6025194
DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence asssociated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: 435/320.1; 435/325, 536/23.1, 536/23.5, 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2 File: USPT Mar 31, 1998

US-PAT-NO: 5733541
DOCUMENT-IDENTIFIER: US 5733541 A
** See image for Certificate of Correction **

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: 424/93.1; 424/93.7, 435/325, 435/347, 435/373, 435/375, 435/377

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

h e b b g e e e f e ef b e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
BMP-2 and L7	2

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: albumin and fusion protein

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Friday, January 16, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L10	l9 adj BMP	980	L10
L9	albumin fusion protein	198014	L9
L8	BMP-2 and L7	2	L8
L7	L6 and IL-6	284	L7
L6	L5 and Rantes	838	L6
L5	human chemokine and albumin	314787	L5
L4	albumin adj2 CXC3	0	L4
L3	albumin fused to BMP	159316	L3
L2	albumin adj2 BMP	1	L2
L1	albumin and fusion protein	144237	L1

END OF SEARCH HISTORY

h e b b g e e e e f ff e ch

US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)

US	2000-249211P	20001117 (60)
US	2000-249215P	20001117 (60)
US	2000-249264P	20001117 (60)
US	2000-249214P	20001117 (60)
US	2000-249297P	20001117 (60)
US	2000-232400P	20000914 (60)
US	2000-231242P	20000908 (60)
US	2000-232081P	20000908 (60)
US	2000-232080P	20000908 (60)
US	2000-231414P	20000908 (60)
US	2000-231244P	20000908 (60)
US	2000-233064P	20000914 (60)
US	2000-233063P	20000914 (60)
US	2000-232397P	20000914 (60)
US	2000-232399P	20000914 (60)
US	2000-232401P	20000914 (60)
US	2000-241808P	20001020 (60)
US	2000-241826P	20001020 (60)
US	2000-241786P	20001020 (60)
US	2000-241221P	20001020 (60)
US	2000-246475P	20001108 (60)
US	2000-231243P	20000908 (60)
US	2000-233065P	20000914 (60)
US	2000-232398P	20000914 (60)
US	2000-234998P	20000925 (60)
US	2000-246477P	20001108 (60)
US	2000-246528P	20001108 (60)
US	2000-246525P	20001108 (60)
US	2000-246476P	20001108 (60)
US	2000-246526P	20001108 (60)
US	2000-249209P	20001117 (60)
US	2000-246527P	20001108 (60)
US	2000-246523P	20001108 (60)
US	2000-246524P	20001108 (60)
US	2000-246478P	20001108 (60)
US	2000-246609P	20001108 (60)
US	2000-246613P	20001108 (60)
US	2000-249300P	20001117 (60)
US	2000-249265P	20001117 (60)
US	2000-246610P	20001108 (60)
US	2000-246611P	20001108 (60)
US	2000-230437P	20000906 (60)
US	2000-251990P	20001208 (60)
US	2000-251988P	20001205 (60)
US	2000-251030P	20001205 (60)
US	2000-251479P	20001206 (60)
US	2000-256719P	20001205 (60)
US	2000-250160P	20001201 (60)
US	2000-251989P	20001208 (60)
US	2000-250391P	20001201 (60)
US	2000-254097P	20001211 (60)
US	2000-231968P	20000912 (60)
US	2000-226279P	20000818 (60)
US	2000-186350P	20000302 (60)
US	2000-184664P	20000224 (60)
US	2000-189874P	20000316 (60)
US	2000-198123P	20000418 (60)
US	2000-227009P	20000823 (60)
US	2000-235484P	20000926 (60)
US	2000-190076P	20000317 (60)
US	2000-209467P	20000607 (60)
US	2000-205515P	20000519 (60)
US	2001-259678P	20010105 (60)
US	2000-179065P	20000131 (60)

US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)

US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)

	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN
TI Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AB Described herein are methods and compositions that can be used for diagnosis and treatment of metastatic colorectal cancer. Also described herein are methods that can be used to identify modulators of metastatic colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334944 USPATFULL
TITLE: Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235820	A1	20031225	
APPLICATION INFO.:	US 2002-87080	A1	20020227	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 22670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1	13014	S RANTES
L2	2849	S ALBUMIN FUSION PROTEIN
L3	8	S L1 AND L2

```
L4          1364 S FGF-8
L5           509 S L4 AND ALBUMIN
L6           491 S L5 AND FUSION
L7           207 S L6 AND L1
L8             0 S L7 AND STABILIZER
L9          6424 S FUSION PARTNER
L10         2467 S L9 AND ALBUMIN
L11          176 S L9 AND BMP
L12          141 S L11 AND L10
L13          101 S L12 AND L1

=> s albumin () fusion protein
L14        2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP
L15           0 ALBUMIN (W) BMP

=> s albumin ()FGF
L16          35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16   ANSWER 1 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58432  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
      vivo. The isolated nucleic acid molecules may be used directly in cell or
      gene therapy applications to treat or prevent liver disorders, including
      hepatic cirrhosis, fulminant liver failure, damage caused by acute viral
      hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAY58432  Protein       DGENE
TITLE:            Fibroblast growth factor family polypeptide which stimulates
                  proliferation and growth of hepatocytes is useful for
                  treating hepatic disorders -
INVENTOR:         Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE:  (AMGE-N)AMGEN INC.
PATENT INFO:      US 5998170    A  19991207                33p
APPLICATION INFO: US 1997-943915   19971003
PRIORITY INFO:    US 1997-943915   19971003
DOCUMENT TYPE:    Patent
LANGUAGE:         English
OTHER SOURCE:     2000-085497 [07]
DESCRIPTION:      Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16   ANSWER 2 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58431  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
```

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene,
biobusiness
```

```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY     SESSION
FULL ESTIMATED COST                                        0.21        0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1         2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
   9 FILES SEARCHED...
L2          193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3            0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2   ANSWER 1 OF 193  USPATFULL on STN
TI     Novel proteins and nucleic acids encoding same
AB     Disclosed herein are nucleic acid sequences that encode novel
       polypeptides. Also disclosed are polypeptides encoded by these nucleic
       acid sequences, and antibodies, which immunospecifically-bind to the
       polypeptide, as well as derivatives, variants, mutants, or fragments of
       the aforementioned polypeptide, polynucleotide, or antibody. The
       invention further discloses therapeutic, diagnostic and research methods
       for diagnosis, treatment, and prevention of disorders involving any one
       of these novel human nucleic acids and proteins.

ACCESSION NUMBER:        2004:13595  USPATFULL
TITLE:                   Novel proteins and nucleic acids encoding same
INVENTOR(S):             Zerhusen, Bryan D., Branford, CT, UNITED STATES
                         Padigaru, Muralidhara, Branford, CT, UNITED STATES
                         Spytek, Kimberly, New Haven, CT, UNITED STATES
                         Spaderna, Steven, Berlin, CT, UNITED STATES
                         Gangolli, Esha A., Branford, CT, UNITED STATES
                         Rastelli, Luca, Guilford, CT, UNITED STATES
```

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Shimkets, Richard, West Haven, CT, UNITED STATES
Mishra, Vishnu, Branford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Szekeres, Edward S., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010118	A1	20040115
APPLICATION INFO.:	US 2001-930512	A1	20010815 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225692P	20000816 (60)
	US 2000-225693P	20000816 (60)
	US 2000-225837P	20000816 (60)
	US 2000-226236P	20000818 (60)
	US 2000-226353P	20000818 (60)
	US 2000-227085P	20000822 (60)
	US 2000-227395P	20000823 (60)
	US 2000-227492P	20000824 (60)
	US 2000-227600P	20000824 (60)
	US 2001-275952P	20010314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
TI Methods of treatment of periodontal disease
AB Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
TITLE: Methods of treatment of periodontal disease
INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
Wozney, John M., Hudson, MA, UNITED STATES
Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009916	A1	20040115
APPLICATION INFO.:	US 2003-397214	A1	20030327 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889 Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328 Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN
TI Chondrogenic and osteogenic inducing molecule
AB The present invention is directed to methods of using and compositions comprising amelogenin peptides capable of inducing chondrogenesis and osteogenesis when implanted in vivo, a chondrogenesis in cultures in vitro. Compositions and methods of enhancing bone and cartilage growth using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6677306	B1	20040113	
	WO 2000006734		20000210	
APPLICATION INFO.:	US 2001-744128		20010516	(9)
	WO 1999-US17342		19990729	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mertz, Prema
LEGAL REPRESENTATIVE: Marshall, Gerstein & Borun LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1877

L2 ANSWER 4 OF 193 USPATFULL on STN
TI Treatment of inflammatory bowel disease using growth factors
AB The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

factors

INVENTOR(S): Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Jeffers, Michael E., Branford, CT, UNITED STATES
LaRochelle, William J., Madison, CT, UNITED STATES
Lichenstein, Henri S., Guilford, CT, UNITED STATES
Peterson, Jeffrey, Brookfield, CT, UNITED STATES
Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
Rittman, Beth, Colchester, CT, UNITED STATES
Shimkets, Juliette B., Guilford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 7115

L2 ANSWER 5 OF 193 USPATFULL on STN
TI Proteins and nucleic acids encoding same
AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
TITLE: Proteins and nucleic acids encoding same
INVENTOR(S): Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., North Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Edinger, Schlomit, New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010620 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 17887

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN
TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:318756 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN
TI Sulfonamide compounds
AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:306969 USPATFULL
TITLE: Sulfonamide compounds
INVENTOR(S): Billledeau, Roland Joseph, Santa Clara, CA, UNITED STATES
Broka, Chris Allen, Foster City, CA, UNITED STATES
Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES
Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES
Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES
Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 3904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN
TI OSTEOPROTEGERIN
AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:294810 USPATFULL
TITLE: OSTEOPROTEGERIN
INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 46 Drawing Page(s)
LINE COUNT: 5457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
L1 2849 S ALBUMIN FUSION PROTEIN
L2 193 S BMP-1 AND ALBUMIN
L3 0 S L2 AND L1

=> s l1 and FGF-16

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1            Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2            "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09    CA/CAplus records now contain indexing from 1907 to the
                    present
 NEWS  4  DEC 08    INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29    DISSABS now available on STN
 NEWS  6  OCT 10    PCTFULL: Two new display fields added
 NEWS  7  OCT 21    BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28    BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24    MSDS-CCOHS file reloaded
 NEWS 10  DEC 08    CABA reloaded with left truncation
 NEWS 11  DEC 08    IMS file names changed
 NEWS 12  DEC 09    Experimental property data collected by CAS now available
                    in REGISTRY
 NEWS 13  DEC 09    STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17    DGENE: Two new display fields added
 NEWS 15  DEC 18    BIOTECHNO no longer updated
 NEWS 16  DEC 19    CROPU no longer updated; subscriber discount no longer
                    available
 NEWS 17  DEC 22    Additional INPI reactions and pre-1907 documents added to CAS
                    databases
 NEWS 18  DEC 22    IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22    ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      0.21        0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s Rantes
L1        13014 RANTES

=> s albumin fusion protein
L2         2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3            8 L1 AND L2

=> d l3 ti abs ibib tot

L3   ANSWER 1 OF 8  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins. Nucleic acid
       molecules encoding the albumin fusion proteins of the invention are also
       encompassed by the invention, as are vectors containing these nucleic
       acids, host cells transformed with these nucleic acids vectors, and
       methods of making the albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating, preventing, or
       ameliorating diseases, disordrs or conditions using albumin fusion
       proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER         KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
```

	US 2000-229358P 20000412 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	25066

L3 ANSWER 2 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:312278 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219875	A1	20031127	
APPLICATION INFO.:	US 2001-833118	A1	20010412	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-256931P	20001221	(60)
	US 2000-199384P	20000425	(60)
	US 2000-229358P	20000412	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	29
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Page(s)
LINE COUNT:	15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN
TI Neutrokine-alpha and neutrokine-alpha splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokine-alpha and neutrokine-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed

on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING

PRIORITY INFORMATION:

NUMBER	DATE
US 2001-329508P	20011017 (60)
US 2001-329747P	20011018 (60)
US 2001-330835P	20011031 (60)
US 2001-331478P	20011116 (60)
US 2001-336726P	20011207 (60)
US 2002-368548P	20020401 (60)
US 2000-225628P	20000815 (60)
US 2000-227008P	20000823 (60)
US 2000-234338P	20000922 (60)
US 2000-240806P	20001017 (60)
US 2000-250020P	20001130 (60)
US 2001-276248P	20010316 (60)
US 2001-293499P	20010525 (60)
US 2001-296122P	20010607 (60)
US 2001-304809P	20010713 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)
US 1999-142659P	19990706 (60)
US 1999-145824P	19990727 (60)
US 1999-167239P	19991124 (60)
US 1999-168624P	19991203 (60)
US 1999-171108P	19991216 (60)
US 1999-171626P	19991223 (60)
US 2000-176015P	20000114 (60)
US 1999-122388P	19990302 (60)
US 1999-124097P	19990312 (60)
US 1999-126599P	19990326 (60)
US 1999-127598P	19990402 (60)
US 1999-130412P	19990416 (60)
US 1999-130696P	19990423 (60)
US 1999-131278P	19990427 (60)
US 1999-131673P	19990429 (60)
US 1999-136784P	19990528 (60)

	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1997-36100P	19970114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	18884	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:244853 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Sadeghi, Homayoun, Doylestown, PA, UNITED STATES Prior, Christopher P., Rosemont, PA, UNITED STATES Turner, Andrew J., Eagleville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171267	A1	20030911	
APPLICATION INFO.:	US 2001-833117	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	59			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	20 Drawing Page(s)			
LINE COUNT:	13208			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:206834 USPATFULL			
TITLE:	Chemokine beta-1 fusion proteins			
INVENTOR(S):	Bell, Adam, Germantown, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143191	A1	20030731	
APPLICATION INFO.:	US 2002-153604	A1	20020524	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-293212P		20010525	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	17			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	21 Drawing Page(s)			
LINE COUNT:	15446			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:181414 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003125247	A1	20030703	
APPLICATION INFO.:	US 2001-833041	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN
TI Binding polypeptides and methods based thereon
AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003091565	A1	20030515	
APPLICATION INFO.:	US 2001-932613	A1	20010817	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 11834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

=> s FGF-8
L4 1364 FGF-8

=> s l4 and albumin
L5 509 L4 AND ALBUMIN

```
=> s l5 and fusion
L6          491 L5 AND FUSION

=> d l6 and l1
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l6 and l1
L7          207 L6 AND L1

=> s l7 and stabilizer
L8            0 L7 AND STABILIZER

=> d l7 ti abs ibib 1-10

L7   ANSWER 1 OF 207  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion
       proteins. Nucleic acid molecules encoding the albumin
       fusion proteins of the invention are also encompassed by the
       invention, as are vectors containing these nucleic acids, host cells
       transformed with these nucleic acids vectors, and methods of making the
       albumin fusion proteins of the invention and using
       these nucleic acids, vectors, and/or host cells. Additionally the
       present invention encompasses pharmaceutical compositions comprising
       albumin fusion proteins and methods of treating,
       preventing, or ameliorating diseases, disordrs or conditions using
       albumin fusion proteins of the invention.

ACCESSION NUMBER:        2004:13611  USPATFULL
TITLE:                   Albumin fusion proteins
INVENTOR(S):             Rosen, Craig A., Laytonsville, MD, UNITED STATES
                         Haseltine, William A., Washington, DC, UNITED STATES

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004010134      A1   20040115
APPLICATION INFO.:       US 2001-833245     A1   20010412  (9)

                              NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-256931P    20001221 (60)
                         US 2000-199384P    20000425 (60)
                         US 2000-229358P    20000412 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
                         ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:        29
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      18 Drawing Page(s)
LINE COUNT:              25066

L7   ANSWER 2 OF 207  USPATFULL on STN
TI     53 human secreted proteins
AB     The present invention relates to novel human secreted proteins and
       isolated nucleic acids containing the coding regions of the genes
       encoding such proteins. Also provided are vectors, host cells,
       antibodies, and recombinant methods for producing human secreted
       proteins. The invention further relates to diagnostic and therapeutic
       methods useful for diagnosing and treating diseases, disorders, and/or
       conditions related to these novel human secreted proteins.

ACCESSION NUMBER:        2004:13609  USPATFULL
```

TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139
Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN
TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L7 ANSWER 4 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L7 ANSWER 5 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12966 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)

US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN
TI Apoptosis inducing molecule II and methods of use
AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
TITLE: Apoptosis inducing molecule II and methods of use
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Zhai, Yifan, Rockville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743 Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520 Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254 Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Page(s)
LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L7 ANSWER 8 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)

US	2000-249212P	20001117 (60)
US	2000-249207P	20001117 (60)
US	2000-249245P	20001117 (60)
US	2000-249244P	20001117 (60)
US	2000-249217P	20001117 (60)
US	2000-249211P	20001117 (60)
US	2000-249215P	20001117 (60)
US	2000-249264P	20001117 (60)
US	2000-249214P	20001117 (60)
US	2000-249297P	20001117 (60)
US	2000-232400P	20000914 (60)
US	2000-231242P	20000908 (60)
US	2000-232081P	20000908 (60)
US	2000-232080P	20000908 (60)
US	2000-231414P	20000908 (60)
US	2000-231244P	20000908 (60)
US	2000-233064P	20000914 (60)
US	2000-233063P	20000914 (60)
US	2000-232397P	20000914 (60)
US	2000-232399P	20000914 (60)
US	2000-232401P	20000914 (60)
US	2000-241808P	20001020 (60)
US	2000-241826P	20001020 (60)
US	2000-241786P	20001020 (60)
US	2000-241221P	20001020 (60)
US	2000-246475P	20001108 (60)
US	2000-231243P	20000908 (60)
US	2000-233065P	20000914 (60)
US	2000-232398P	20000914 (60)
US	2000-234998P	20000925 (60)
US	2000-246477P	20001108 (60)
US	2000-246528P	20001108 (60)
US	2000-246525P	20001108 (60)
US	2000-246476P	20001108 (60)
US	2000-246526P	20001108 (60)
US	2000-249209P	20001117 (60)
US	2000-246527P	20001108 (60)
US	2000-246523P	20001108 (60)
US	2000-246524P	20001108 (60)
US	2000-246478P	20001108 (60)
US	2000-246609P	20001108 (60)
US	2000-246613P	20001108 (60)
US	2000-249300P	20001117 (60)
US	2000-249265P	20001117 (60)
US	2000-246610P	20001108 (60)
US	2000-246611P	20001108 (60)
US	2000-230437P	20000906 (60)
US	2000-251990P	20001208 (60)
US	2000-251988P	20001205 (60)
US	2000-251030P	20001205 (60)
US	2000-251479P	20001206 (60)
US	2000-256719P	20001205 (60)
US	2000-250160P	20001201 (60)
US	2000-251989P	20001208 (60)
US	2000-250391P	20001201 (60)
US	2000-254097P	20001211 (60)
US	2000-231968P	20000912 (60)
US	2000-226279P	20000818 (60)
US	2000-186350P	20000302 (60)
US	2000-184664P	20000224 (60)
US	2000-189874P	20000316 (60)
US	2000-198123P	20000418 (60)
US	2000-227009P	20000823 (60)
US	2000-235484P	20000926 (60)

	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	27694	

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL	
TITLE:	Nucleic acids, proteins, and antibodies	
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES	
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)

US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

```
L1         13014 S RANTES
L2          2849 S ALBUMIN FUSION PROTEIN
L3             8 S L1 AND L2
L4          1364 S FGF-8
L5           509 S L4 AND ALBUMIN
L6           491 S L5 AND FUSION
L7           207 S L6 AND L1
L8             0 S L7 AND STABILIZER

=> s fusion partner
L9          6424 FUSION PARTNER

=> s l9 and albumin
L10         2467 L9 AND ALBUMIN

=> s l9 and BMP
L11          176 L9 AND BMP

=> s l11 and l10
L12          141 L11 AND L10

=> s l12 and l1
L13          101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13  ANSWER 1 OF 101  USPATFULL on STN
TI     Albumin fusion proteins
AB     The present invention encompasses albumin fusion proteins.
       Nucleic acid molecules encoding the albumin fusion proteins of
       the invention are also encompassed by the invention, as are vectors
       containing these nucleic acids, host cells transformed with these
       nucleic acids vectors, and methods of making the albumin
       fusion proteins of the invention and using these nucleic acids, vectors,
       and/or host cells. Additionally the present invention encompasses
       pharmaceutical compositions comprising albumin fusion proteins
       and methods of treating, preventing, or ameliorating diseases, disordrs
       or conditions using albumin fusion proteins of the invention.
```

ACCESSION NUMBER:	2004:13611 USPATFULL			
TITLE:	Albumin fusion proteins			
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010134	A1	20040115	
APPLICATION INFO.:	US 2001-833245	A1	20010412	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-256931P		20001221	(60)
	US 2000-199384P		20000425	(60)
	US 2000-229358P		20000412	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850			
NUMBER OF CLAIMS:	29			
EXEMPLARY CLAIM:	1			

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18144

L13 ANSWER 3 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

	US 2000-249209P	20001117 (60)
	US 2000-246527P	20001108 (60)
	US 2000-246523P	20001108 (60)
	US 2000-246524P	20001108 (60)
	US 2000-246478P	20001108 (60)
	US 2000-246609P	20001108 (60)
	US 2000-246613P	20001108 (60)
	US 2000-249300P	20001117 (60)
	US 2000-249265P	20001117 (60)
	US 2000-246610P	20001108 (60)
	US 2000-246611P	20001108 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-231968P	20000912 (60)
	US 2000-226279P	20000818 (60)
	US 2000-186350P	20000302 (60)
	US 2000-184664P	20000224 (60)
	US 2000-189874P	20000316 (60)
	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	32038	

L13 ANSWER 4 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 18130

L13 ANSWER 5 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US	2000-217496P	20000711 (60)
US	2000-225447P	20000814 (60)
US	2000-218290P	20000714 (60)
US	2000-225757P	20000814 (60)
US	2000-226868P	20000822 (60)
US	2000-216647P	20000707 (60)
US	2000-225267P	20000814 (60)
US	2000-216880P	20000707 (60)
US	2000-225270P	20000814 (60)
US	2000-251869P	20001208 (60)
US	2000-235834P	20000927 (60)
US	2000-234274P	20000921 (60)
US	2000-234223P	20000921 (60)
US	2000-228924P	20000830 (60)
US	2000-224518P	20000814 (60)
US	2000-236369P	20000929 (60)
US	2000-224519P	20000814 (60)
US	2000-220964P	20000726 (60)
US	2000-241809P	20001020 (60)
US	2000-249299P	20001117 (60)
US	2000-236327P	20000929 (60)
US	2000-241785P	20001020 (60)
US	2000-244617P	20001101 (60)
US	2000-225268P	20000814 (60)
US	2000-236368P	20000929 (60)
US	2000-251856P	20001208 (60)
US	2000-251868P	20001208 (60)
US	2000-229344P	20000901 (60)
US	2000-234997P	20000925 (60)
US	2000-229343P	20000901 (60)
US	2000-229345P	20000901 (60)
US	2000-229287P	20000901 (60)
US	2000-229513P	20000905 (60)
US	2000-231413P	20000908 (60)
US	2000-229509P	20000905 (60)
US	2000-236367P	20000929 (60)
US	2000-237039P	20001002 (60)
US	2000-237038P	20001002 (60)
US	2000-236370P	20000929 (60)
US	2000-236802P	20001002 (60)
US	2000-237037P	20001002 (60)
US	2000-237040P	20001002 (60)
US	2000-240960P	20001020 (60)
US	2000-239935P	20001013 (60)
US	2000-239937P	20001013 (60)
US	2000-241787P	20001020 (60)
US	2000-246474P	20001108 (60)
US	2000-246532P	20001108 (60)
US	2000-249216P	20001117 (60)
US	2000-249210P	20001117 (60)
US	2000-226681P	20000822 (60)
US	2000-225759P	20000814 (60)
US	2000-225213P	20000814 (60)
US	2000-227182P	20000822 (60)
US	2000-225214P	20000814 (60)
US	2000-235836P	20000927 (60)
US	2000-230438P	20000906 (60)
US	2000-215135P	20000630 (60)
US	2000-225266P	20000814 (60)
US	2000-249218P	20001117 (60)
US	2000-249208P	20001117 (60)
US	2000-249213P	20001117 (60)
US	2000-249212P	20001117 (60)
US	2000-249207P	20001117 (60)

US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)

	US 2000-205515P 20000519 (60)
	US 2001-259678P 20010105 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
LINE COUNT:	27694

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER:	2004:7341 USPATFULL
TITLE:	Nucleic acids, proteins, and antibodies
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)

US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)

US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE°
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334955 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)

US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)

US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
US 2000-179065P 20000131 (60)

US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)

US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)
US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)

	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN
TI Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AB Described herein are methods and compositions that can be used for diagnosis and treatment of metastatic colorectal cancer. Also described herein are methods that can be used to identify modulators of metastatic colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334944 USPATFULL
TITLE: Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235820	A1	20031225	
APPLICATION INFO.:	US 2002-87080	A1	20020227	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 22670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1	13014	S RANTES
L2	2849	S ALBUMIN FUSION PROTEIN
L3	8	S L1 AND L2

```
L4        1364 S FGF-8
L5         509 S L4 AND ALBUMIN
L6         491 S L5 AND FUSION
L7         207 S L6 AND L1
L8           0 S L7 AND STABILIZER
L9        6424 S FUSION PARTNER
L10       2467 S L9 AND ALBUMIN
L11        176 S L9 AND BMP
L12        141 S L11 AND L10
L13        101 S L12 AND L1

=> s albumin () fusion protein
L14       2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP
L15          0 ALBUMIN (W) BMP

=> s albumin ()FGF
L16         35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16   ANSWER 1 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58432  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
      vivo. The isolated nucleic acid molecules may be used directly in cell or
      gene therapy applications to treat or prevent liver disorders, including
      hepatic cirrhosis, fulminant liver failure, damage caused by acute viral
      hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAY58432  Protein       DGENE
TITLE:            Fibroblast growth factor family polypeptide which stimulates
                  proliferation and growth of hepatocytes is useful for
                  treating hepatic disorders -
INVENTOR:         Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE:  (AMGE-N)AMGEN INC.
PATENT INFO:      US 5998170    A  19991207                33p
APPLICATION INFO: US 1997-943915   19971003
PRIORITY INFO:    US 1997-943915   19971003
DOCUMENT TYPE:    Patent
LANGUAGE:         English
OTHER SOURCE:     2000-085497 [07]
DESCRIPTION:      Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16   ANSWER 2 OF 35  DGENE  COPYRIGHT 2004 THOMSON DERWENT on STN
TI    Fibroblast growth factor family polypeptide which stimulates
      proliferation and growth of hepatocytes is useful for treating hepatic
      disorders -
AN    AAY58431  Protein       DGENE
AB    This sequence represents a truncated rat fibroblast growth factor-16
      (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16
      (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
      hepatocyte proliferation and growth activity, and increases hepatic
      production of triglycerides and serum proteins (e.g., albumin).
      FGF-16 nucleic acids and/or proteins may be used for stimulating
      the proliferation and development of hepatocytes both in vitro and in
```

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.
ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a pAMG21 vector PCR primer used to ascertain that a pAMG21/rat FGF-16 construct had been produced in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.
ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N) AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55804 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55804 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55803 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55802 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55802 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55801 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55800 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55800 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55799 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55799 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID NO:14.

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55798 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55798 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55797 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55794 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55793 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.
ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.
ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58429
DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55790 cDNA DGENE
AB This sequence represents cDNA encoding rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF**-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
ACCESSION NUMBER: AAZ55790 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: P-PSDB: AAY58428
DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1	13014	S	RANTES
L2	2849	S	ALBUMIN FUSION PROTEIN
L3	8	S	L1 AND L2
L4	1364	S	FGF-8
L5	509	S	L4 AND ALBUMIN
L6	491	S	L5 AND FUSION
L7	207	S	L6 AND L1
L8	0	S	L7 AND STABILIZER
L9	6424	S	FUSION PARTNER
L10	2467	S	L9 AND ALBUMIN
L11	176	S	L9 AND BMP
L12	141	S	L11 AND L10
L13	101	S	L12 AND L1
L14	2849	S	ALBUMIN () FUSION PROTEIN
L15	0	S	ALBUMIN () BMP
L16	35	S	ALBUMIN ()FGF

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1 File: USPT Jan 7, 1986

US-PAT-NO: 4563489
DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Urist; Marshall R.	Pacific Palisades	CA		

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
albumin adj2 BMP	1

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2 File: USPT Feb 15, 2000

US-PAT-NO: 6025194
DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence asssociated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: 435/320.1; 435/325, 536/23.1, 536/23.5, 536/24.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2 File: USPT Mar 31, 1998

US-PAT-NO: 5733541
DOCUMENT-IDENTIFIER: US 5733541 A
** See image for Certificate of Correction **

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: 424/93.1; 424/93.7, 435/325, 435/347, 435/373, 435/375, 435/377

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

h e b b g e e e f e ef b e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
BMP-2 and L7	2

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

Freeform Search

Database:
- US Pre-Grant Publication Full-Text Database
- **US Patents Full-Text Database**
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Term: albumin and fusion protein

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Interrupt

Search History

DATE: Friday, January 16, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L10	l9 adj BMP	980	L10
L9	albumin fusion protein	198014	L9
L8	BMP-2 and L7	2	L8
L7	L6 and IL-6	284	L7
L6	L5 and Rantes	838	L6
L5	human chemokine and albumin	314787	L5
L4	albumin adj2 CXC3	0	L4
L3	albumin fused to BMP	159316	L3
L2	albumin adj2 BMP	1	L2
L1	albumin and fusion protein	144237	L1

END OF SEARCH HISTORY

h e b b g e e e e f ff e ch